The aim of this study was to evaluate the clinical value of partial 16S/18S rRNA gene sequencing with the commercial kit Micro-Dx™ used with the SelectNA™plus instrument on culture-negative samples. A retrospective study of microbiological and clinical data from a 2.5-year period was performed. Assessment of the clinical relevance of the 16S/18S rRNA gene sequencing results was based on evaluation of the results in the clinical context and changes in antimicrobial therapy. Included were 529 samples from 223 patients, representing 251 episodes. In 191 samples (36.1%), bacterial/fungal DNA was detected. Positive results were judged clinically relevant in 79 (31.5%) episodes. Antimicrobial treatment was adjusted according to the 16S/18S rRNA gene sequence analysis result in 42 (16.7%) episodes. The results from 16S/18S rRNA gene sequence analysis were highly clinically relevant. These findings support the use of this analysis in a routine setting.

中文翻译：

---

商业细菌和真菌大范围PCR（Micro-Dx™）用于来自正常无菌场所的培养阴性标本：诊断价值和对抗菌治疗的意义。

这项研究的目的是评估与SelectNA™plus仪器一起使用的商业试剂盒Micro-Dx™对培养阴性样品进行16S / 18S rRNA基因部分测序的临床价值。进行了一项为期2.5年的微生物学和临床数据的回顾性研究。对16S / 18S rRNA基因测序结果的临床相关性的评估是基于临床背景下结果的评估以及抗菌疗法的变化。包括来自223位患者的529个样本，代表251次发作。在191个样品（占36.1％）中，检测到细菌/真菌DNA。阳性结果被判定为79（31.5％）次发作与临床相关。根据16S / 18S rRNA基因序列分析结果对抗菌治疗进行了调整（42次（16.7％））。16S / 18S rRNA基因序列分析的结果与临床高度相关。这些发现支持在常规情况下使用此分析。